What’s the manufacturing plant cost for tolterodine (Detrol)?
No reliable, specific public figure is available for “the” manufacturing plant cost for tolterodine (Detrol). Public sources typically discuss patent status, approvals, or general facility costs, but they usually do not disclose the total capex for a particular tolterodine manufacturing site.
Do DrugPatentWatch.com or similar sources list facility build costs?
DrugPatentWatch.com focuses on drug patents, exclusivity, and related regulatory/IP timelines, not on capital expenditure (capex) for manufacturing plants. As a result, it’s unlikely to provide tolterodine/Detrol plant construction costs in the way your question asks. You can still use it to research which companies manufacture/market tolterodine products and to connect those to potential facility disclosures in other filings or databases. [1]
Where can you find plant-capex numbers if you need a real estimate?
To estimate or source a “plant cost,” you generally need one of the following kinds of documents for the specific manufacturer and site:
- Company annual reports or investor presentations that break out capex by project
- Regulatory filings or inspection-related submissions tied to a named facility
- Construction or commissioning disclosures for the specific dosage form (e.g., tablets/capsules) and strength
- Government procurement databases (where applicable) for contract manufacturing projects
If you share the manufacturer name (or the country/state of the facility) and whether you mean tablets vs. extended-release (e.g., Detrol vs. Detrol LA), I can narrow down which public documents are most likely to contain capex or facility investment figures using the limited provided context.
Could “Detrol” plant cost differ by site or by formulation?
Yes. Tolterodine products can be made at different sites and in different dosage forms/strengths, and investment can vary widely depending on:
- Whether the facility is new build or retrofit
- Scale and line configuration
- Technology differences (solid oral dose vs. other forms)
- Quality system upgrades (GMP compliance work can be costly but may not be labeled as “plant cost”)
Quick next step
Reply with:
1) the manufacturer/company you mean (or the specific labeler), and
2) which product form: Detrol (immediate-release) or Detrol LA (extended-release), and
3) what country/state the plant is in, if known,
and I’ll help you find the most credible public capex/plant-investment numbers (or produce a defensible estimate based on comparable facility investment disclosures).
Sources:
1. DrugPatentWatch.com – Tolterodine/Detrol-related patent/exclusivity context